

Title (en)
ANTI-TNFALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF

Title (de)
ANTI-TNF-ALPHA-ANTIKÖRPER UND FUNKTIONALE FRAGMENTE DAVON

Title (fr)
ANTICORPS ANTI-TNF ALPHA ET FRAGMENTS FONCTIONNELS DE CEUX-CI

Publication
EP 4275745 A3 20231220 (EN)

Application
EP 23192170 A 20170316

Priority
• EP 16160907 A 20160317
• EP 17710748 A 20170316
• EP 2017056237 W 20170316

Abstract (en)
The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF α), to processes for their production, and to their therapeutic uses.

IPC 8 full level
C07K 16/24 (2006.01); **A61K 39/395** (2006.01); **A61P 1/00** (2006.01); **A61P 1/04** (2006.01); **A61P 29/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP KR US)
A61P 1/00 (2018.01 - EP KR); **A61P 1/04** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP);
C07K 16/241 (2013.01 - EP KR US); **A61K 2039/505** (2013.01 - KR); **C07K 2317/24** (2013.01 - EP US); **C07K 2317/33** (2013.01 - EP KR US);
C07K 2317/622 (2013.01 - EP KR US); **C07K 2317/626** (2013.01 - EP US); **C07K 2317/73** (2013.01 - EP); **C07K 2317/76** (2013.01 - EP US);
C07K 2317/92 (2013.01 - EP KR US); **C07K 2317/94** (2013.01 - EP)

Citation (search report)
• [A] EP 2623515 A1 20130807 - CHENGDU KANGHONG BIOTECHNOLOGIES CO LTD [CN]
• [A] WO 2012007880 A2 20120119 - ABLYNX NV [BE], et al
• [A] WO 2015144852 A1 20151001 - DELENEX THERAPEUTICS AG [CH]
• [A] WO 2015065987 A1 20150507 - IBC PHARMACEUTICALS INC [US]
• [A] MARIA WIEKOWSKI ET AL: "Infliximab (Remicade)", 1 January 2007 (2007-01-01), XP002720018, ISBN: 978-3-527-31453-9, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1002/9783527619740.ch34/pdf> [retrieved on 20140210]
• [A] HARTMUT KUPPER ET AL: "Adalimumab (Humira)", 1 January 2007 (2007-01-01), XP002720017, ISBN: 978-3-527-31453-9, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1002/9783527619740.ch27/pdf> [retrieved on 20140210]
• [A] MELMED GIL Y ET AL: "Certolizumab pegol", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 7, no. 8, 1 August 2008 (2008-08-01), pages 641 - 642, XP009147828, ISSN: 1474-1784, DOI: 10.1038/NRD2654
• [A] MAZUMDAR SOHINI ET AL: "Golimumab", MABS, LANDES BIOSCIENCE, US, vol. 1, no. 5, 1 September 2009 (2009-09-01), pages 422 - 431, XP002631538, ISSN: 1942-0870
• [A] "CDP 571: anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade", DRUGS IN R & D, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 4, no. 3, 1 January 2003 (2003-01-01), pages 174 - 178, XP009176085, ISSN: 1174-5886
• [A] TRACEY ET AL: "Tumor necrosis factor antagonist mechanisms of action: A comprehensive review", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 117, no. 2, 26 October 2007 (2007-10-26), pages 244 - 279, XP022432143, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2007.10.001

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
MA MD

DOCDB simple family (publication)
EP 3219726 A1 20170920; EP 3219726 B1 20201202; AR 107917 A1 20180628; AU 2017235387 A1 20180927; AU 2017235387 B2 20240627; BR 112018016667 A2 20190205; CA 3011784 A1 20170921; CA 3011784 C 20240423; CL 2018002649 A1 20181109; CN 109071650 A 20181221; CN 109071650 B 20220513; CO 2018009783 A2 20180928; CR 20180448 A 20190125; CY 1123784 T1 20220527; DK 3219726 T3 20201207; DK 3430043 T3 20231127; EA 039760 B1 20220310; EA 201891788 A1 20190131; EP 3430043 A1 20190123; EP 3430043 B1 20230830; EP 4275745 A2 20231115; EP 4275745 A3 20231220; ES 2836349 T3 20210624; ES 2963221 T3 20240326; FI 3430043 T3 20231117; GE P20217307 B 20211025; HR P20210123 T1 20210305; HR P20231464 T1 20240301; HU E052773 T2 20210528; HU E064238 T2 20240228; IL 261031 A 20181031; JO P20170064 B1 20210817; JO P20210085 A1 20230130; JP 2019512268 A 20190516; JP 2022130407 A 20220906; JP 7129398 B2 20220901; KR 102470235 B1 20221124; KR 20180120149 A 20181105; KR 20220158877 A 20221201; LT 3219726 T 20210125; LT 3430043 T 20231227; MA 43717 A 20181128; MA 43717 B1 20231130; MD 3430043 T2 20240229; MX 2018011258 A 20190213; MY 194041 A 20221109; PH 12018501907 A1 20190617; PL 3219726 T3 20210719; PL 3430043 T3 20240311; PT 3219726 T 20201215; PT 3430043 T 20231123; RS 61374 B1 20210226; RS 64830 B1 20231229; SA 518400027 B1 20220306; SG 11201807062R A 20180927; SI 3219726 T1 20210226; SI 3430043 T1 20240131; TN 2018000298 A1 20200116; TW 201739766 A 20171116; TW 202311288 A 20230316; TW I784945 B 20221201; TW I829444 B 20240111; US 11459383 B2 20221004; US 2021198353 A1 20210701; US 2023272059 A1 20230831; US 2023279091 A1 20230907; UY 37157 A 20171031; WO 2017158092 A1 20170921; ZA 202108599 B 20220330; ZA 202108600 B 20220330; ZA 202108601 B 20220330; ZA 202108602 B 20220330

DOCDB simple family (application)
EP 16160907 A 20160317; AR P170100675 A 20170317; AU 2017235387 A 20170316; BR 112018016667 A 20170316; CA 3011784 A 20170316; CL 2018002649 A 20180914; CN 201780015298 A 20170316; CO 2018009783 A 20180917; CR 20180448 A 20170316; CY 211100021 T 20210113; DK 16160907 T 20160317; DK 17710748 T 20170316; EA 201891788 A 20170316; EP 17710748 A 20170316; EP 2017056237 W 20170316; EP 23192170 A 20170316; ES 16160907 T 20160317; ES 17710748 T 20170316;

FI 17710748 T 20170316; GE AP2017014876 A 20170316; HR P20210123 T 20210122; HR P20231464 T 20170316;
HU E16160907 A 20160317; HU E17710748 A 20170316; IL 26103118 A 20180807; JO P20170064 A 20170316; JO P20210085 A 20210422;
JP 2019500013 A 20170316; JP 2022091271 A 20220606; KR 20187022632 A 20170316; KR 20227040533 A 20170316;
LT 16160907 T 20160317; LT EP2017056237 T 20170316; MA 43717 A 20170316; MD E20190099 T 20170316; MX 2018011258 A 20170316;
MY PI2018001566 A 20170316; PH 12018501907 A 20180906; PL 16160907 T 20160317; PL 17710748 T 20170316;
PT 16160907 T 20160317; PT 17710748 T 20170316; RS P20210112 A 20160317; RS P20231087 A 20170316; SA 518400027 A 20180916;
SG 11201807062R A 20170316; SI 201631040 T 20160317; SI 201731446 T 20170316; TN 2018000298 A 20170316;
TW 106108832 A 20170317; TW 111145252 A 20170317; US 201716085506 A 20170316; US 202217890857 A 20220818;
US 202217958759 A 20221003; UY 37157 A 20170317; ZA 202108599 A 20211104; ZA 202108600 A 20211104; ZA 202108601 A 20211104;
ZA 202108602 A 20211104